1.7M
XNAS Volume
High volume today
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 8,500 | 87,292 (0%) | 0% | 0 | Common stock | |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 18,000 | 36,000 | - | - | Restricted stock units | |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 8,500 | 8,500 | - | - | Restricted stock units | |
| Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 142,500 | 142,500 | - | - | Stock options (right to buy) | |
| Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 39,000 | 39,000 | - | - | Restricted stock units | |
| Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 8,794 | 92,345 (0%) | 0% | 35.5 | 312,539 | Common stock |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 18,000 | 101,139 (0%) | 0% | 0 | Common stock | |
| Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 4,153 | 83,139 (0%) | 0% | 35.5 | 147,598 | Common stock |
| Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 594 | 21,843 (0%) | 0% | 35.5 | 21,111 | Common stock |
| Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,000 | 22,437 (0%) | 0% | 0 | Common stock | |
| Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 11,333 | - | - | Restricted stock units | |
| Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,000 | 2,000 | - | - | Restricted stock units | |
| Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 43,500 | 43,500 | - | - | Stock options (right to buy) | |
| Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 15,910 | 15,910 | - | - | Restricted stock units | |
| Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 12,000 | 12,000 | - | - | Restricted stock units | |
| Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 25,829 (0%) | 0% | 35.5 | 59,743 | Common stock |
| Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 27,510 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,000 | 4,000 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,833 | 48,235 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,137 | 47,098 (0%) | 0% | 35.5 | 40,409 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,000 | 51,098 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,187 | 49,911 (0%) | 0% | 35.5 | 42,186 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 55,578 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 53,897 (0%) | 0% | 35.5 | 59,743 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 12,000 | 12,000 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 43,500 | 43,500 | - | - | Stock options (right to buy) | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,833 | 0 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 11,333 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 727 | 9,414 (0%) | 0% | 35.5 | 25,838 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 697 | 7,691 (0%) | 0% | 35.5 | 24,771 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 777 | 6,269 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 231 | 6,038 (0%) | 0% | 35.5 | 8,210 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,350 | 8,388 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,450 | 10,141 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,450 | 4,900 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 2,350 | 2,350 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 777 | 0 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 6,142 | 6,142 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 8,085 | 8,085 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 11,333 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 12,000 | 12,000 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 11,759 | 11,759 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 43,500 | 43,500 | - | - | Stock options (right to buy) | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,833 | 0 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,000 | 4,000 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 3,833 | 19,787 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,137 | 18,650 (0%) | 0% | 35.5 | 40,409 | Common stock |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 4,000 | 22,650 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,187 | 21,463 (0%) | 0% | 35.5 | 42,186 | Common stock |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 27,130 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 25,449 (0%) | 0% | 35.5 | 59,743 | Common stock |
| Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 24,573 (0%) | 0% | 0 | Common stock | |
| Tsveta Milanova | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 12,000 | 12,000 | - | - | Restricted stock units | |
| Tsveta Milanova | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 43,500 | 43,500 | - | - | Stock options (right to buy) | |
| Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 5,667 | 11,333 | - | - | Restricted stock units | |
| Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 35.54 per share. | 01 Mar 2025 | 1,681 | 22,892 (0%) | 0% | 35.5 | 59,743 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 6,896 | 7,709 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 34.39 per share. | 01 Feb 2025 | 2,272 | 5,437 (0%) | 0% | 34.4 | 78,134 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 6,896 | 0 | - | - | Restricted stock units | |
| Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 8,476 | 21,710 (0%) | 0% | 0 | Common stock | |
| Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 32.18 per share. | 03 Jan 2025 | 2,804 | 18,906 (0%) | 0% | 32.2 | 90,233 | Common stock |
| Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 8,476 | 8,475 | - | - | Restricted stock units | |
| David Scadden T. | Director | Sale of securities on an exchange or to another person at price $ 46.28 per share. | 11 Dec 2024 | 200 | 15,483 (0%) | 0% | 46.3 | 9,256 | Common stock |
| Scadden David T. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2024 | 200 | 29,107 | - | - | Stock options (right to buy) | |
| T. David Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 11 Dec 2024 | 200 | 15,683 (0%) | 0% | 18.1 | 3,618 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 56.09 per share. | 08 Nov 2024 | 772 | 813 (0%) | 0% | 56.1 | 43,301 | Common stock |
| Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 53.32 per share. | 07 Nov 2024 | 8,132 | 9,860 (0%) | 0% | 53.3 | 433,598 | Common stock |
| Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 10,000 | 27,947 | - | - | Stock option (right to buy) | |
| Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 10,000 | 17,947 | - | - | Stock option (right to buy) | |
| Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 54.41 per share. | 07 Nov 2024 | 1,868 | 7,992 (0%) | 0% | 54.4 | 101,638 | Common stock |
| Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.99 per share. | 07 Nov 2024 | 10,000 | 17,992 (0%) | 0% | 26.0 | 259,900 | Common stock |
| Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 59.21 per share. | 07 Nov 2024 | 1,500 | 7,992 (0%) | 0% | 59.2 | 88,815 | Common stock |
| Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 58.57 per share. | 07 Nov 2024 | 4,929 | 9,492 (0%) | 0% | 58.6 | 288,692 | Common stock |
| Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 57.24 per share. | 07 Nov 2024 | 3,571 | 14,421 (0%) | 0% | 57.2 | 204,404 | Common stock |
| Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.99 per share. | 07 Nov 2024 | 10,000 | 17,992 (0%) | 0% | 26.0 | 259,900 | Common stock |
| James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 52.00 per share. | 07 Nov 2024 | 13,411 | 24,041 (0%) | 0% | 52 | 697,372 | Common stock |
| James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 52.56 per share. | 07 Nov 2024 | 8,341 | 15,700 (0%) | 0% | 52.6 | 438,403 | Common stock |
| Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2024 | 7,473 | 22,700 (0%) | 0% | 0 | Common stock | |
| Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.03 per share. | 26 Sep 2024 | 2,542 | 20,158 (0%) | 0% | 49.0 | 124,634 | Common stock |
| Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2024 | 7,473 | 7,472 | - | - | Restricted stock units | |
| Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2024 | 2,302 | 7,992 (0%) | 0% | 0 | Common stock | |
| Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2024 | 2,302 | 2,302 | - | - | Restricted stock units | |
| Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2024 | 2,302 | 7,992 (0%) | 0% | 0 | Common stock | |
| Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2024 | 2,302 | 2,302 | - | - | Restricted stock units | |
| Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.75 per share. | 08 Aug 2024 | 11,091 | 78,792 (0%) | 0% | 42.7 | 474,140 | Common stock |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 22,691 | 22,691 | - | - | Restricted stock units | |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 22,691 | 89,883 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 8,375 | 47,441 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 43.85 per share. | 01 Jul 2024 | 3,705 | 43,736 (0%) | 0% | 43.8 | 162,464 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 8,375 | 16,749 | - | - | Restricted stock units | |
| Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| David P. Schenkein | Director | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | ||
| David P. Schenkein | Director | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | ||
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 1,976 | 1,976 (0%) | 0% | 0 | Common stock | |
| Jeffrey D. Capello | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 1,976 | 3,953 | - | - | Restricted stock units | |
| Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 8,912 (0%) | 0% | 0 | Common stock | |
| Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| Kaye Foster | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jun 2024 | 3,564 | 5,348 (0%) | 0% | 0 | Common stock | |
| Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 140,784 (0%) | 0% | 0 | Common stock | |
| Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 5,690 (0%) | 0% | 0 | Common stock | |
| Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| David P. Schenkein | Director | 13 Jun 2024 | 3,388 | 126,242 (0%) | 0% | 0 | Common stock | ||
| David P. Schenkein | Director | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | ||
| Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 14,912 (0%) | 0% | 0 | Common stock | |
| David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 15,483 (0%) | 0% | 0 | Common stock | |
| Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 5,690 (0%) | 0% | 0 | Common stock | |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2024 | 25,527 | 79,307 (0%) | 0% | 0 | Common stock | |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2024 | 25,527 | 76,583 | - | - | Performance share units | |
| Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 48.84 per share. | 05 Jun 2024 | 12,115 | 67,192 (0%) | 0% | 48.8 | 591,697 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 44.39 per share. | 03 Jun 2024 | 1,362 | 1,524 (0%) | 0% | 44.4 | 60,459 | Common stock |
| Jacqualyn A. Fouse | Director | Sale of securities on an exchange or to another person at price $ 27.55 per share. | 08 Apr 2024 | 7,791 | 137,396 (0%) | 0% | 27.5 | 214,642 | Common stock |
| Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 15,934 | 15,933 | - | - | Restricted stock units | |
| Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 15,934 | 145,187 (0%) | 0% | 0 | Common stock | |
| Kaye Foster | Director | Sale of securities on an exchange or to another person at price $ 31.62 per share. | 07 Mar 2024 | 1,285 | 5,524 (0%) | 0% | 31.6 | 40,632 | Common stock |
| Kaye Foster | Director | Sale of securities on an exchange or to another person at price $ 32.21 per share. | 05 Mar 2024 | 300 | 11,224 (0%) | 0% | 32.2 | 9,663 | Common stock |
| Kaye Foster | Director | Sale of securities on an exchange or to another person at price $ 31.99 per share. | 05 Mar 2024 | 4,415 | 6,809 (0%) | 0% | 32.0 | 141,236 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 31.75 per share. | 05 Mar 2024 | 1,913 | 2,886 (0%) | 0% | 31.8 | 60,738 | Common stock |
| Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 195,500 | 195,500 | - | - | Stock options (right to buy) | |
| Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 54,000 | 54,000 | - | - | Restricted stock units | |
| Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 4,156 | 53,780 (0%) | 0% | 32.6 | 135,361 | Common stock |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 8,500 | 57,936 (0%) | 0% | 0 | Common stock | |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 8,500 | 17,000 | - | - | Restricted stock units | |
| Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 2,000 | 4,000 | - | - | Restricted stock units | |
| Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 17,000 | 17,000 | - | - | Restricted stock units | |
| Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 672 | 14,840 (0%) | 0% | 32.6 | 21,887 | Common stock |
| Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 2,000 | 15,512 (0%) | 0% | 0 | Common stock | |
| Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 60,000 | 60,000 | - | - | Stock options (right to buy) | |
| Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 17,000 | 17,000 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 4,000 | 40,415 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 1,293 | 36,415 (0%) | 0% | 32.6 | 42,113 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 3,834 | 37,708 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 4,000 | 8,000 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 3,834 | 3,833 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 60,000 | 60,000 | - | - | Stock options (right to buy) | |
| Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 1,349 | 39,066 (0%) | 0% | 32.6 | 43,937 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 2,350 | 5,718 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 295 | 3,368 (0%) | 0% | 32.6 | 9,608 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 777 | 3,663 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 2,350 | 4,700 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 777 | 777 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 7,350 | 7,350 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 919 | 4,799 (0%) | 0% | 32.6 | 29,932 | Common stock |
| James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 1,349 | 37,169 (0%) | 0% | 32.6 | 43,937 | Common stock |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 3,834 | 3,833 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 60,000 | 60,000 | - | - | Stock options (right to buy) | |
| James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 17,000 | 17,000 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 4,000 | 8,000 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 4,000 | 38,518 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 32.57 per share. | 01 Mar 2024 | 1,293 | 34,518 (0%) | 0% | 32.6 | 42,113 | Common stock |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 3,834 | 35,811 (0%) | 0% | 0 | Common stock | |
| Tsveta Milanova | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 17,000 | 17,000 | - | - | Restricted stock units | |
| Tsveta Milanova | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 60,000 | 60,000 | - | - | Stock options (right to buy) | |
| Schenkein David P. | Director | 27 Feb 2024 | 11,858 | 57,471 | - | - | Stock option (right to buy) | ||
| Schenkein P. David | Director | 27 Feb 2024 | 57,471 | 122,854 (0%) | 0% | 34.9 | 2,005,163 | Common stock | |
| P. Schenkein David | Director | 27 Feb 2024 | 11,858 | 122,854 (0%) | 0% | 33.6 | 398,429 | Common stock | |
| David Schenkein P. | Director | 27 Feb 2024 | 57,471 | 180,325 (0%) | 0% | 31.6 | 1,818,382 | Common stock | |
| Schenkein David P. | Director | 27 Feb 2024 | 11,858 | 134,712 (0%) | 0% | 31.6 | 375,187 | Common stock | |
| P. David Schenkein | Director | 27 Feb 2024 | 57,471 | 0 | - | - | Stock option (right to buy) | ||
| David Schenkein P. | Director | 23 Feb 2024 | 20,411 | 143,265 (0%) | 0% | 31.6 | 645,804 | Common stock | |
| David P. Schenkein | Director | 23 Feb 2024 | 47,731 | 89,740 | - | - | Stock option (right to buy) | ||
| P. Schenkein David | Director | 23 Feb 2024 | 47,731 | 122,854 (0%) | 0% | 33.1 | 1,577,510 | Common stock | |
| P. Schenkein David | Director | 23 Feb 2024 | 47,731 | 170,585 (0%) | 0% | 31.6 | 1,510,209 | Common stock | |
| P. David Schenkein | Director | 23 Feb 2024 | 20,411 | 122,854 (0%) | 0% | 33.2 | 677,441 | Common stock | |
| P. David Schenkein | Director | 23 Feb 2024 | 20,411 | 69,329 | - | - | Stock option (right to buy) | ||
| Washburn J. T. | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 26.63 per share. | 20 Feb 2024 | 504 | 2,741 (0%) | 0% | 26.6 | 13,422 | Common stock |
| Gheuens Sarah | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.14 per share. | 12 Feb 2024 | 642 | 33,431 (0%) | 0% | 25.1 | 16,140 | Common stock |
| William James Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 1,833 | 0 | - | - | Restricted stock units | |
| J. Washburn T. | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 25.14 per share. | 12 Feb 2024 | 273 | 3,245 (0%) | 0% | 25.1 | 6,863 | Common stock |
| Washburn T. J. | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 777 | 3,518 (0%) | 0% | 0 | Common stock | |
| Burns James William | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.14 per share. | 12 Feb 2024 | 545 | 31,666 (0%) | 0% | 25.1 | 13,701 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 2,162 | 0 | - | - | Restricted stock units | |
| Burns James William | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 1,833 | 32,211 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 2,162 | 34,073 (0%) | 0% | 0 | Common stock | |
| Washburn J. T. | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 777 | 0 | - | - | Restricted stock units | |
| Jacqualyn Fouse A. | Director | Sale of securities on an exchange or to another person at price $ 21.64 per share. | 20 Jan 2024 | 10,722 | 129,253 (0%) | 0% | 21.6 | 232,024 | Common stock |
| Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,448 | 0 | - | - | Performance share units | |
| Gheuens Sarah | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,750 | 0 | - | - | Performance share units | |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 17,018 | 102,110 | - | - | Performance share units | |
| Jones Cecilia | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.64 per share. | 20 Jan 2024 | 1,886 | 13,069 (0%) | 0% | 21.6 | 40,813 | Common stock |
| William Burns James | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,750 | 32,086 (0%) | 0% | 0 | Common stock | |
| Jones Cecilia | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,380 | 0 | - | - | Performance share units | |
| Jacqualyn Fouse A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 23,900 | 0 | - | - | Performance share units | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,750 | 33,619 (0%) | 0% | 0 | Common stock | |
| Milanova Tsveta | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 21.64 per share. | 20 Jan 2024 | 1,618 | 13,234 (0%) | 0% | 21.6 | 35,014 | Common stock |
| James Burns William | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,750 | 0 | - | - | Performance share units | |
| Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.64 per share. | 20 Jan 2024 | 1,708 | 31,911 (0%) | 0% | 21.6 | 36,961 | Common stock |
| Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 21.64 per share. | 20 Jan 2024 | 7,635 | 49,436 (0%) | 0% | 21.6 | 165,221 | Common stock |
| William James Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 21.64 per share. | 20 Jan 2024 | 1,708 | 30,378 (0%) | 0% | 21.6 | 36,961 | Common stock |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 17,018 | 57,071 (0%) | 0% | 0 | Common stock | |
| Fouse Jacqualyn A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 23,900 | 139,975 (0%) | 0% | 0 | Common stock | |
| Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,380 | 14,955 (0%) | 0% | 0 | Common stock | |
| Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 5,448 | 14,852 (0%) | 0% | 0 | Common stock | |
| Goff Brian | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 25,527 | 52,119 (0%) | 0% | 0 | Common stock | |
| Goff Brian | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 22.99 per share. | 05 Jan 2024 | 12,066 | 40,053 (0%) | 0% | 23.0 | 277,397 | Common stock |
| Gheuens Sarah | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.99 per share. | 05 Jan 2024 | 1,789 | 27,869 (0%) | 0% | 23.0 | 41,129 | Common stock |
| Fouse Jacqualyn A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 17,500 | 124,466 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 5,000 | 29,658 (0%) | 0% | 0 | Common stock | |
| James Burns William | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 22.99 per share. | 05 Jan 2024 | 1,163 | 26,336 (0%) | 0% | 23.0 | 26,737 | Common stock |
| William James Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 3,250 | 0 | - | - | Performance share units | |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 25,527 | 119,128 | - | - | Performance share units | |
| A. Fouse Jacqualyn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 17,500 | 0 | - | - | Performance share units | |
| Gheuens Sarah | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 5,000 | 0 | - | - | Performance share units | |
| A. Fouse Jacqualyn | Director | Sale of securities on an exchange or to another person at price $ 22.99 per share. | 05 Jan 2024 | 8,391 | 116,075 (0%) | 0% | 23.0 | 192,909 | Common stock |
| James Burns William | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 3,250 | 27,499 (0%) | 0% | 0 | Common stock | |
| Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2024 | 8,475 | 12,306 (0%) | 0% | 0 | Common stock | |
| Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.32 per share. | 03 Jan 2024 | 2,902 | 9,404 (0%) | 0% | 22.3 | 64,773 | Common stock |
| Milanova Tsveta | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2024 | 8,475 | 16,951 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 26.28 per share. | 17 Aug 2023 | 6,395 | 23,890 (0%) | 0% | 26.3 | 168,061 | Common stock |
| Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 2,302 | 2,302 (0%) | 0% | 0 | Common stock | |
| Cynthia Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 2,302 | 4,604 | - | - | Restricted stock units | |
| Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 2,302 | 2,302 (0%) | 0% | 0 | Common stock | |
| Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 2,302 | 4,604 | - | - | Restricted stock units | |
| Kaye Foster | Director | Sale of securities on an exchange or to another person at price $ 25.96 per share. | 09 Aug 2023 | 25,000 | 11,524 (0%) | 0% | 26.0 | 648,888 | Common stock |
| Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2023 | 25,000 | 4,307 | - | - | Stock options (right to buy) | |
| Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 09 Aug 2023 | 25,000 | 36,524 (0%) | 0% | 18.1 | 452,250 | Common stock |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 22,691 | 36,770 (0%) | 0% | 0 | Common stock | |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 22,691 | 45,382 | - | - | Restricted stock units | |
| Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.48 per share. | 08 Aug 2023 | 10,178 | 26,592 (0%) | 0% | 25.5 | 259,335 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 25.39 per share. | 07 Aug 2023 | 2,918 | 2,741 (0%) | 0% | 25.4 | 74,096 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2023 | 4,150 | 6,891 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2023 | 4,150 | 0 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 26.26 per share. | 01 Aug 2023 | 1,232 | 5,659 (0%) | 0% | 26.3 | 32,352 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2023 | 25,124 | 25,124 | - | - | Restricted stock units | |
| Jacqualyn A. Fouse | Director | Sale of securities on an exchange or to another person at price $ 28.36 per share. | 28 Jun 2023 | 10,718 | 106,966 (0%) | 0% | 28.4 | 303,962 | Common stock |
| Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 23,900 | 23,900 | - | - | Performance share units | |
| Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 23,900 | 117,684 (0%) | 0% | 0 | Common stock | |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 25,528 | 25,528 (0%) | 0% | 0 | Common stock | |
| Brian Goff | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 25,528 | 144,655 | - | - | Performance share units | |
| Brian Goff | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.36 per share. | 28 Jun 2023 | 11,449 | 14,079 (0%) | 0% | 28.4 | 324,694 | Common stock |
| Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,380 | 5,380 (0%) | 0% | 0 | Common stock | |
| Cecilia Jones | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,380 | 5,380 | - | - | Performance share units | |
| Cecilia Jones | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.36 per share. | 28 Jun 2023 | 1,597 | 3,783 (0%) | 0% | 28.4 | 45,291 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,750 | 5,750 | - | - | Performance share units | |
| Sarah Gheuens | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.36 per share. | 28 Jun 2023 | 1,707 | 24,159 (0%) | 0% | 28.4 | 48,411 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,750 | 25,866 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.36 per share. | 28 Jun 2023 | 1,707 | 30,285 (0%) | 0% | 28.4 | 48,411 | Common stock |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,750 | 5,750 | - | - | Performance share units | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,750 | 31,992 (0%) | 0% | 0 | Common stock | |
| Tsveta Milanova | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.36 per share. | 28 Jun 2023 | 1,618 | 3,831 (0%) | 0% | 28.4 | 45,886 | Common stock |
| Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,449 | 5,448 | - | - | Performance share units | |
| Tsveta Milanova | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 5,449 | 5,449 (0%) | 0% | 0 | Common stock | |
| Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 4,975 | 0 | - | - | Restricted stock unit | |
| Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 4,975 | 11,524 (0%) | 0% | 0 | Common stock | |
| David P. Schenkein | Director | 21 Jun 2023 | 4,975 | 0 | - | - | Restricted stock unit | ||
| David P. Schenkein | Director | 21 Jun 2023 | 4,975 | 122,854 (0%) | 0% | 0 | Common stock | ||
| Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 4,975 | 11,524 (0%) | 0% | 0 | Common stock | |
| Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 4,975 | 0 | - | - | Restricted stock unit | |
| David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 4,975 | 0 | - | - | Restricted stock unit | |
| David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 4,975 | 12,095 (0%) | 0% | 0 | Common stock | |
| Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 5,929 | 5,929 | - | - | Restricted stock units | |
| Jeffrey D. Capello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 33,177 | 33,177 | - | - | Stock options (right to buy) | |
| Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| David P. Schenkein | Director | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | ||
| David P. Schenkein | Director | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | ||
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2023 | 15,933 | 98,515 (0%) | 0% | 0 | Common stock | |
| Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2023 | 15,933 | 31,867 | - | - | Restricted stock units | |
| Jacqualyn A. Fouse | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.35 per share. | 08 Apr 2023 | 4,731 | 93,784 (0%) | 0% | 21.4 | 101,007 | Common stock |
| David P. Schenkein | Director | 03 Apr 2023 | 16,363 | 134,242 (0%) | 0% | 9.0 | 148,085 | Common stock | |
| David P. Schenkein | Director | 03 Apr 2023 | 16,363 | 117,879 (0%) | 0% | 22.9 | 373,895 | Common stock | |
| David P. Schenkein | Director | 03 Apr 2023 | 16,363 | 0 | - | - | Stock option (right to buy) | ||
| David P. Schenkein | Director | 27 Mar 2023 | 20,000 | 137,879 (0%) | 0% | 9.1 | 181,000 | Common stock | |
| David P. Schenkein | Director | 27 Mar 2023 | 20,000 | 16,363 | - | - | Stock option (right to buy) | ||
| David P. Schenkein | Director | 27 Mar 2023 | 20,000 | 117,879 (0%) | 0% | 22.2 | 443,000 | Common stock | |
| David P. Schenkein | Director | 13 Mar 2023 | 18,333 | 119,546 (0%) | 0% | 22.5 | 411,943 | Common stock | |
| David P. Schenkein | Director | 13 Mar 2023 | 20,000 | 137,879 (0%) | 0% | 9.1 | 181,000 | Common stock | |
| David P. Schenkein | Director | 13 Mar 2023 | 1,667 | 117,879 (0%) | 0% | 22.7 | 37,874 | Common stock | |
| David P. Schenkein | Director | 13 Mar 2023 | 20,000 | 36,363 | - | - | Stock option (right to buy) | ||
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 24.29 per share. | 03 Mar 2023 | 504 | 2,741 (0%) | 0% | 24.3 | 12,242 | Common stock |
| Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 94,500 | 94,500 | - | - | Stock options (right to buy) | |
| Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 25,500 | 25,500 | - | - | Restricted stock units | |
| Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 22,000 | 22,000 | - | - | Stock options (right to buy) | |
| Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 6,000 | 6,000 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 44,000 | 44,000 | - | - | Stock options (right to buy) | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 3,833 | 21,250 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.02 per share. | 01 Mar 2023 | 1,134 | 20,116 (0%) | 0% | 25.0 | 28,373 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 12,000 | 12,000 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 3,833 | 7,667 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 777 | 3,518 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.31 per share. | 01 Mar 2023 | 273 | 3,245 (0%) | 0% | 25.3 | 6,910 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 7,050 | 7,050 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 777 | 1,554 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 3,833 | 27,371 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 3,833 | 7,667 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.02 per share. | 01 Mar 2023 | 1,129 | 26,242 (0%) | 0% | 25.0 | 28,248 | Common stock |
| James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 12,000 | 12,000 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 44,000 | 44,000 | - | - | Stock options (right to buy) | |
| David P. Schenkein | Director | 27 Feb 2023 | 20,000 | 137,879 (0%) | 0% | 9.1 | 181,000 | Common stock | |
| David P. Schenkein | Director | 27 Feb 2023 | 20,000 | 56,363 | - | - | Stock option (right to buy) | ||
| David P. Schenkein | Director | 27 Feb 2023 | 20,000 | 117,879 (0%) | 0% | 25.4 | 507,400 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 27.21 per share. | 16 Feb 2023 | 233 | 2,668 (0%) | 0% | 27.2 | 6,340 | Common stock |
| Jacqualyn A. Fouse | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 14 Feb 2023 | 3,648 | 82,582 (0%) | 0% | 28.9 | 105,464 | Common stock |
| Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 11,333 | 0 | - | - | Restricted stock units | |
| Jacqualyn A. Fouse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 11,333 | 86,230 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.59 per share. | 14 Feb 2023 | 504 | 2,901 (0%) | 0% | 28.6 | 14,409 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 360 | 0 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 14 Feb 2023 | 127 | 3,405 (0%) | 0% | 28.9 | 3,672 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 360 | 3,532 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.91 per share. | 14 Feb 2023 | 609 | 23,538 (0%) | 0% | 28.9 | 17,606 | Common stock |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 1,738 | 0 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 1,738 | 24,147 (0%) | 0% | 0 | Common stock | |
| David P. Schenkein | Director | 13 Feb 2023 | 20,000 | 137,879 (0%) | 0% | 9.1 | 181,000 | Common stock | |
| David P. Schenkein | Director | 13 Feb 2023 | 20,000 | 117,879 (0%) | 0% | 28.6 | 572,400 | Common stock | |
| David P. Schenkein | Director | 13 Feb 2023 | 20,000 | 76,363 | - | - | Stock option (right to buy) | ||
| Sarah Gheuens | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.44 per share. | 10 Feb 2023 | 758 | 17,009 (0%) | 0% | 28.4 | 21,558 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,162 | 2,162 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,162 | 17,767 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,834 | 23,052 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,834 | 1,833 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.44 per share. | 10 Feb 2023 | 643 | 22,409 (0%) | 0% | 28.4 | 18,287 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.44 per share. | 01 Feb 2023 | 273 | 3,172 (0%) | 0% | 28.4 | 7,764 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 777 | 777 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 6,896 | 6,896 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 777 | 3,445 (0%) | 0% | 0 | Common stock | |
| David P. Schenkein | Director | 30 Jan 2023 | 20,000 | 137,879 (0%) | 0% | 9.1 | 181,000 | Common stock | |
| David P. Schenkein | Director | 30 Jan 2023 | 20,000 | 96,363 | - | - | Stock option (right to buy) | ||
| David P. Schenkein | Director | 30 Jan 2023 | 3,300 | 117,879 (0%) | 0% | 29.9 | 98,604 | Common stock | |
| David P. Schenkein | Director | 30 Jan 2023 | 16,700 | 121,179 (0%) | 0% | 29.2 | 487,974 | Common stock | |
| David P. Schenkein | Director | 17 Jan 2023 | 18,966 | 118,913 (0%) | 0% | 28.8 | 546,600 | Common stock | |
| David P. Schenkein | Director | 17 Jan 2023 | 20,000 | 116,363 | - | - | Stock option (right to buy) | ||
| David P. Schenkein | Director | 17 Jan 2023 | 1,034 | 117,879 (0%) | 0% | 29.5 | 30,493 | Common stock | |
| David P. Schenkein | Director | 17 Jan 2023 | 20,000 | 137,879 (0%) | 0% | 9.1 | 181,000 | Common stock | |
| Kaye Foster | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Jan 2023 | 2,200 | 6,549 (0%) | 0% | 0 | Common stock | |
| Tsveta Milanova | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 135,682 | 135,682 | - | - | Stock option (right to buy) | |
| Tsveta Milanova | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 25,426 | 25,426 | - | - | Restricted stock units | |
| John M. Maraganore | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 1,500 | 28,528 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2022 | 9,375 | 0 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.48 per share. | 23 Dec 2022 | 2,783 | 15,605 (0%) | 0% | 28.5 | 79,260 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2022 | 9,375 | 18,388 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2022 | 8,750 | 0 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2022 | 8,750 | 23,815 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.48 per share. | 23 Dec 2022 | 2,597 | 21,218 (0%) | 0% | 28.5 | 73,963 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.83 per share. | 02 Dec 2022 | 248 | 9,013 (0%) | 0% | 28.8 | 7,150 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 833 | 0 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 833 | 9,261 (0%) | 0% | 0 | Common stock | |
| Richa Poddar | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.48 per share. | 15 Oct 2022 | 1,485 | 8,508 (0%) | 0% | 27.5 | 40,808 | Common stock |
| Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2022 | 5,000 | 0 | - | - | Restricted stock units | |
| Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2022 | 5,000 | 9,993 (0%) | 0% | 0 | Common stock | |
| Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2022 | 22,417 | 22,417 | - | - | Restricted stock units | |
| Cecilia Jones | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2022 | 118,390 | 118,390 | - | - | Stock options (right to buy) | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 6,906 | 6,906 | - | - | Restricted stock units | |
| Cynthia Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 37,947 | 37,947 | - | - | Stock option (right to buy) | |
| Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 6,906 | 6,906 | - | - | Restricted stock units | |
| Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 37,947 | 37,947 | - | - | Stock option (right to buy) | |
| Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2022 | 68,073 | 68,073 | - | - | Restricted stock units | |
| Brian Goff | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2022 | 561,083 | 561,083 | - | - | Stock option (right to buy) | |
| John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | |
| John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | |
| Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | |
| Kaye Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | |
| David P. Schenkein | Director | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | ||
| David P. Schenkein | Director | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | ||
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | |
| Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | |
| David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | |
| David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | |
| Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 6,549 (0%) | 0% | 0 | Common stock | |
| John M. Maraganore | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 30,028 (0%) | 0% | 0 | Common stock | |
| John M. Maraganore | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| Kaye Foster | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 8,749 (0%) | 0% | 0 | Common stock | |
| Paul J. Clancy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| Paul J. Clancy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 6,549 (0%) | 0% | 0 | Common stock | |
| David P. Schenkein | Director | 20 May 2022 | 1,585 | 117,879 (0%) | 0% | 0 | Common stock | ||
| David P. Schenkein | Director | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | ||
| Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 6,549 (0%) | 0% | 0 | Common stock | |
| Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 7,120 (0%) | 0% | 0 | Common stock | |
| Jacqualyn A. Fouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2022 | 47,800 | 47,800 | - | - | Restricted stock units | |
| Jacqualyn A. Fouse | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2022 | 170,000 | 170,000 | - | - | Stock options (right to buy) | |
| Jonathan Biller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,500 | 11,500 | - | - | Restricted stock units | |
| Jonathan Biller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 41,000 | 41,000 | - | - | Stock options (right to buy) | |
| Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 41,000 | 41,000 | - | - | Stock options (right to buy) | |
| Bruce Car | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,500 | 11,500 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 41,000 | 41,000 | - | - | Stock options (right to buy) | |
| Sarah Gheuens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,500 | 11,500 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 1,165 | 1,165 | - | - | Stock options (right to buy) | |
| T. J. Washburn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 2,331 | 2,331 | - | - | Restricted stock units | |
| Richa Poddar | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 41,000 | 41,000 | - | - | Stock options (right to buy) | |
| Richa Poddar | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,500 | 11,500 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 41,000 | 41,000 | - | - | Stock options (right to buy) | |
| James William Burns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,500 | 11,500 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 25 Feb 2022 | 108 | 2,549 (0%) | 0% | 30 | 3,240 | Common stock |
| David P. Schenkein | Director | 22 Feb 2022 | 2,775 | 0 | - | - | Restricted stock units | ||
| David P. Schenkein | Director | 22 Feb 2022 | 2,775 | 117,052 (0%) | 0% | 0 | Common stock | ||
| David P. Schenkein | Director | 22 Feb 2022 | 758 | 116,294 (0%) | 0% | 29.1 | 22,043 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 22 Feb 2022 | 59 | 2,657 (0%) | 0% | 29.1 | 1,716 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 167 | 0 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 167 | 2,716 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 724 | 15,008 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 724 | 0 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 22 Feb 2022 | 215 | 14,793 (0%) | 0% | 29.1 | 6,252 | Common stock |
| Jacqualyn A. Fouse | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 18 Feb 2022 | 3,674 | 74,897 (0%) | 0% | 29.1 | 106,840 | Common stock |
| Jacqualyn A. Fouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 12,379 | 12,380 | - | - | Performance share units | |
| Jacqualyn A. Fouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 12,379 | 78,571 (0%) | 0% | 0 | Common stock | |
| Jonathan Biller | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 8,523 | 8,522 | - | - | Performance share units | |
| Jonathan Biller | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 8,523 | 25,641 (0%) | 0% | 0 | Common stock | |
| Jonathan Biller | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 18 Feb 2022 | 2,688 | 22,953 (0%) | 0% | 29.1 | 78,167 | Common stock |
| Bruce Car | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 18 Feb 2022 | 2,041 | 16,752 (0%) | 0% | 29.1 | 59,352 | Common stock |
| Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 6,874 | 6,874 | - | - | Performance share units | |
| Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 6,874 | 18,793 (0%) | 0% | 0 | Common stock | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 3,271 | 3,272 | - | - | Performance share units | |
| Sarah Gheuens | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 18 Feb 2022 | 955 | 7,768 (0%) | 0% | 29.1 | 27,771 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 3,271 | 8,723 (0%) | 0% | 0 | Common stock | |
| Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 1,884 | 1,883 | - | - | Performance share units | |
| Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 658 | 0 | - | - | Restricted stock units | |
| Richa Poddar | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.08 per share. | 18 Feb 2022 | 742 | 4,441 (0%) | 0% | 29.1 | 21,577 | Common stock |
| Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 658 | 5,183 (0%) | 0% | 0 | Common stock | |
| Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 1,884 | 4,525 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 30.81 per share. | 16 Feb 2022 | 233 | 2,549 (0%) | 0% | 30.8 | 7,179 | Common stock |
| Jacqualyn A. Fouse | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.50 per share. | 14 Feb 2022 | 3,505 | 66,192 (0%) | 0% | 30.5 | 106,903 | Common stock |
| Jacqualyn A. Fouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 11,334 | 11,333 | - | - | Restricted stock units | |
| Jacqualyn A. Fouse | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 11,334 | 69,697 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 360 | 360 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 31.25 per share. | 14 Feb 2022 | 504 | 2,782 (0%) | 0% | 31.3 | 15,750 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.50 per share. | 14 Feb 2022 | 127 | 3,286 (0%) | 0% | 30.5 | 3,874 | Common stock |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 360 | 3,413 (0%) | 0% | 0 | Common stock | |
| Richa Poddar | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.50 per share. | 14 Feb 2022 | 590 | 2,641 (0%) | 0% | 30.5 | 17,995 | Common stock |
| Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 1,738 | 1,738 | - | - | Restricted stock units | |
| Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 1,738 | 3,231 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 5,250 | 16,439 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 1,738 | 1,738 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 5,250 | 0 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 1,738 | 11,189 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.50 per share. | 14 Feb 2022 | 2,155 | 14,284 (0%) | 0% | 30.5 | 65,728 | Common stock |
| Jonathan Biller | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. | 10 Feb 2022 | 1,349 | 17,118 (0%) | 0% | 31.4 | 42,392 | Common stock |
| Jonathan Biller | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 3,667 | 7,333 | - | - | Restricted stock units | |
| Jonathan Biller | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 3,667 | 18,467 (0%) | 0% | 0 | Common stock | |
| Bruce Car | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. | 10 Feb 2022 | 1,073 | 11,919 (0%) | 0% | 31.4 | 33,719 | Common stock |
| Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 3,667 | 12,992 (0%) | 0% | 0 | Common stock | |
| Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 3,667 | 7,333 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. | 10 Feb 2022 | 758 | 5,452 (0%) | 0% | 31.4 | 23,820 | Common stock |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 2,162 | 4,324 | - | - | Restricted stock units | |
| Sarah Gheuens | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 2,162 | 6,210 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 777 | 1,554 | - | - | Restricted stock units | |
| T. J. Washburn | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 777 | 3,292 (0%) | 0% | 0 | Common stock | |
| T. J. Washburn | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. | 10 Feb 2022 | 273 | 3,019 (0%) | 0% | 31.4 | 8,579 | Common stock |
| Richa Poddar | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. | 10 Feb 2022 | 725 | 1,493 (0%) | 0% | 31.4 | 22,783 | Common stock |
| Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 2,068 | 4,136 | - | - | Restricted stock units | |
| Richa Poddar | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 2,068 | 2,218 (0%) | 0% | 0 | Common stock | |
| James William Burns | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.42 per share. | 10 Feb 2022 | 643 | 9,451 (0%) | 0% | 31.4 | 20,206 | Common stock |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 1,833 | 3,667 | - | - | Restricted stock units | |
| James William Burns | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 1,833 | 10,094 (0%) | 0% | 0 | Common stock | |
| Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2022 | 3,437 | 10,530 (0%) | 0% | 0 | Common stock | |
| Bruce Car | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2022 | 3,437 | 3,437 | - | - | Restricted stock units | |
| Bruce Car | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.58 per share. | 06 Jan 2022 | 1,205 | 9,325 (0%) | 0% | 32.6 | 39,259 | Common stock |
| Carman Alenson | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 61.61 per share. | 21 Jun 2021 | 1,777 | 0 (0%) | 0% | 61.6 | 109,481 | Common stock |
| Carman Alenson | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2021 | 1,777 | 3,555 | - | - | Stock option (right to buy) | |
| Carman Alenson | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.51 per share. | 21 Jun 2021 | 1,777 | 1,777 (0%) | 0% | 51.5 | 91,533 | Common stock |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 50.40 per share. | 18 Jun 2021 | 46,608 | 63,980 (0%) | 0% | 50.4 | 2,349,043 | Common stock |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2021 | 46,608 | 992 | - | - | Stock option (right to buy) | |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2021 | 1,885 | 0 | - | - | Stock option (right to buy) | |
| Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.11 per share. | 18 Jun 2021 | 48,493 | 15,487 (0%) | 0% | 60.1 | 2,914,851 | Common stock |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 18 Jun 2021 | 1,885 | 17,372 (0%) | 0% | 39.8 | 74,948 | Common stock |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 17 Jun 2021 | 2,502 | 17,989 (0%) | 0% | 39.8 | 99,480 | Common stock |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 2,502 | 1,885 | - | - | Stock option (right to buy) | |
| Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.02 per share. | 17 Jun 2021 | 2,502 | 15,487 (0%) | 0% | 60.0 | 150,170 | Common stock |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 09 Jun 2021 | 7,149 | 22,636 (0%) | 0% | 39.8 | 284,244 | Common stock |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2021 | 20,853 | 4,387 | - | - | Stock option (right to buy) | |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2021 | 7,149 | 25,240 | - | - | Stock option (right to buy) | |
| Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.06 per share. | 09 Jun 2021 | 20,853 | 15,487 (0%) | 0% | 60.1 | 1,252,437 | Common stock |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 09 Jun 2021 | 20,853 | 36,340 (0%) | 0% | 39.8 | 829,115 | Common stock |
| Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.16 per share. | 09 Jun 2021 | 7,149 | 15,487 (0%) | 0% | 60.2 | 430,117 | Common stock |
| Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.04 per share. | 07 Jun 2021 | 4,268 | 15,487 (0%) | 0% | 60.0 | 256,232 | Common stock |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 6,675 | 32,389 | - | - | Stock option (right to buy) | |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 4,268 | 39,064 | - | - | Stock option (right to buy) | |
| Christopher Bowden | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.07 per share. | 07 Jun 2021 | 6,675 | 15,487 (0%) | 0% | 60.1 | 400,939 | Common stock |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 07 Jun 2021 | 6,675 | 22,162 (0%) | 0% | 39.8 | 265,398 | Common stock |
| Christopher Bowden | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.76 per share. | 07 Jun 2021 | 4,268 | 19,755 (0%) | 0% | 39.8 | 169,696 | Common stock |